| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Purity: ≥98%
Azilsartan Medoxomil (formerly also known as TAK-491), the ester prodrug of Azilsartan (TAK-536), is a potent and orally bioavailable angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM. It is used for the treatment of hypertension. Azilsartan lowers blood pressure by blocking the action of angiotensin II. Azilsartan also inhibits the accumulation of AII-induced inositol 1-phosphate (IP1) in the cell-based assay with an IC50 value of 9.2 nM. Azilsartan medoxomil is a useful and attractive new option for lowering BP in patients with essential hypertension, particularly for those not able to tolerate other antihypertensive drugs.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
During absorption, azilsartan cilexetil is hydrolyzed to azilsartan. After oral administration, the parent drug is undetectable in plasma. The absolute bioavailability of azilsartan is estimated at 60%. The time to peak concentration (Tmax) is 1.5 to 3 hours. Steady-state plasma concentrations of azilsartan are reached within 5 days, and repeated once-daily dosing does not lead to plasma accumulation. Following oral administration of 14C-labeled azilsartan cilexetil, approximately 55% of the radioactive material is recovered in feces, and approximately 42% is recovered in urine. Of the dose recovered in urine, approximately 15% is excreted as azilsartan. The volume of distribution of azilsartan is approximately 16 liters. In rats, very small amounts of the radiolabeled drug cross the blood-brain barrier. Azilsartan can cross the placental barrier in pregnant rats and distribute to the fetus. The renal clearance of azilsartan is approximately 2.3 mL/min. Metabolism/Metabolites Azilsartan ester is hydrolyzed into its active metabolite, which is further metabolized into two major metabolites, neither of which has pharmacological activity. The major metabolite in plasma is metabolite M-II, which is generated by an O-dealkylation reaction mediated by CYP2C9. The minor metabolite is metabolite MI, which is generated by decarboxylation reactions mediated by CYP2C8 and CYP2B6. The systemic exposure of azilsartan in MII is approximately 50%, while the systemic exposure of azilsartan in MI is less than 1%. Biological Half-Life The elimination half-life of azilsartan is approximately 11 hours. |
||
| Toxicity/Toxicokinetics |
Protein Binding
Azilsartan binds to human plasma proteins (primarily serum albumin) at a rate >99%. Even when plasma azilsartan concentrations are well above the recommended dose range, its protein binding remains constant. |
||
| References |
J Pharmacol Exp Ther.2011 Mar;336(3):801-8;Am J Hypertens.2007 May;20(5):579-86.
|
||
| Additional Infomation |
Pharmacodynamics
The pharmacodynamic effects of azilsartan cilexetil are mediated by its active metabolite, azilsartan. Azilsartan inhibits the pressor effect induced by angiotensin II infusion in a dose-dependent manner. A single 32 mg dose of azilsartan inhibits approximately 90% of the maximal pressor effect at peak plasma concentration and approximately 60% at 24 hours post-dose. In healthy subjects, single and repeated doses of azilsartan cilexetil resulted in increased plasma angiotensin I and II concentrations and plasma renin activity, while plasma aldosterone concentrations decreased. Like other angiotensin receptor blockers (ARBs), azilsartan dose-dependently reduces peripheral resistance and vascular smooth muscle tone. Because azilsartan blocks angiotensin II receptors, the negative feedback regulation of renin secretion by angiotensin II is inhibited; however, the resulting increase in plasma renin activity and circulating angiotensin II levels does not offset the antihypertensive effect of azilsartan. The antihypertensive effect of antihypertensive drugs may be diminished in African American patients. However, there are currently no recommendations to adjust azilsartan dosage based on patient sex, race, or the degree of renal or hepatic impairment. Azilsartan ester has negligible effects on serum potassium or sodium levels. Azilsartan does not affect angiotensin II biosynthesis or bradykinin levels. It also does not bind to any ion channels involved in cardiovascular regulation. |
| Molecular Formula |
C30H24N4O8
|
|---|---|
| Molecular Weight |
568.53
|
| Exact Mass |
568.159
|
| Elemental Analysis |
C, 63.38; H, 4.26; N, 9.85; O, 22.51
|
| CAS # |
863031-21-4
|
| Related CAS # |
Azilsartan;147403-03-0;Azilsartan-d5;1346599-45-8;Azilsartan medoxomil monopotassium;863031-24-7
|
| PubChem CID |
135409642
|
| Appearance |
Solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
748.0±70.0 °C at 760 mmHg
|
| Flash Point |
406.2±35.7 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.680
|
| LogP |
5.73
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
42
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC(COC(C2C3=C(N=C(N3CC3C=CC(C4C(C5NC(=O)ON=5)=CC=CC=4)=CC=3)OCC)C=CC=2)=O)=C(C)O1
|
| InChi Key |
QJFSABGVXDWMIW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
|
| Chemical Name |
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate
|
| Synonyms |
TAK-491; TAK 491; TAK491; Azilsartan medoxomil; Azilsartan medoxomil potassium; trade name: Edarbi. Ipreziv.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7589 mL | 8.7946 mL | 17.5892 mL | |
| 5 mM | 0.3518 mL | 1.7589 mL | 3.5178 mL | |
| 10 mM | 0.1759 mL | 0.8795 mL | 1.7589 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.